These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 16697188)

  • 21. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
    Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
    Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer.
    Yan Y; Lu Y; Wang M; Vikis H; Yao R; Wang Y; Lubet RA; You M
    Mol Cancer Res; 2006 Dec; 4(12):971-81. PubMed ID: 17189387
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ZD1839 (IRESSA): a selective EGFR-TK inhibitor.
    Ranson M; Mansoor W; Jayson G
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):161-8. PubMed ID: 12113238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
    Li B; Chang CM; Yuan M; McKenna WG; Shu HK
    Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
    Van Schaeybroeck S; Karaiskou-McCaul A; Kelly D; Longley D; Galligan L; Van Cutsem E; Johnston P
    Clin Cancer Res; 2005 Oct; 11(20):7480-9. PubMed ID: 16243822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.
    Yang G; Yao Y; Zhou J; Zhao Q
    Oncol Rep; 2012 Jun; 27(6):2066-72. PubMed ID: 22446631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the epidermal growth factor receptor in non-small cell lung cancer.
    Herbst RS; Bunn PA
    Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5813-24. PubMed ID: 14676101
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.
    Guillamo JS; de Boüard S; Valable S; Marteau L; Leuraud P; Marie Y; Poupon MF; Parienti JJ; Raymond E; Peschanski M
    Clin Cancer Res; 2009 Jun; 15(11):3697-704. PubMed ID: 19435839
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
    Knowlden JM; Jones HE; Barrow D; Gee JM; Nicholson RI; Hutcheson IR
    Breast Cancer Res Treat; 2008 Sep; 111(1):79-91. PubMed ID: 17902048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.
    Ko JC; Ciou SC; Cheng CM; Wang LH; Hong JH; Jheng MY; Ling ST; Lin YW
    Carcinogenesis; 2008 Jul; 29(7):1448-58. PubMed ID: 18544565
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
    Höpfner M; Sutter AP; Huether A; Schuppan D; Zeitz M; Scherübl H
    J Hepatol; 2004 Dec; 41(6):1008-16. PubMed ID: 15582135
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.
    Choi YJ; Rho JK; Jeon BS; Choi SJ; Park SC; Lee SS; Kim HR; Kim CH; Lee JC
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):381-8. PubMed ID: 19921194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimization of gefitinib analogues with potent anticancer activity.
    Yin KH; Hsieh YH; Sulake RS; Wang SP; Chao JI; Chen C
    Bioorg Med Chem Lett; 2014 Nov; 24(22):5247-50. PubMed ID: 25305687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
    Liu H; Li L; Li XQ; Liu XJ; Zhen YS
    Anticancer Drugs; 2009 Jan; 20(1):41-9. PubMed ID: 19342999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
    Von Pawel J
    Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
    Wakeling AE; Guy SP; Woodburn JR; Ashton SE; Curry BJ; Barker AJ; Gibson KH
    Cancer Res; 2002 Oct; 62(20):5749-54. PubMed ID: 12384534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase.
    Abouzid K; Shouman S
    Bioorg Med Chem; 2008 Aug; 16(16):7543-51. PubMed ID: 18678492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).
    Siegel-Lakhai WS; Beijnen JH; Schellens JH
    Oncologist; 2005 Sep; 10(8):579-89. PubMed ID: 16177282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Fontanini G; Cuccato S; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2001 May; 7(5):1459-65. PubMed ID: 11350918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.